1. Home
  2. Analysis
  3. Lansoprazole
  4. Obliterative-bronchiolitis

Lansoprazole and Obliterative bronchiolitis - a phase IV clinical study of FDA data

Summary:

Obliterative bronchiolitis is reported as a side effect among people who take Lansoprazole (lansoprazole), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Methotrexate, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Obliterative bronchiolitis when taking Lansoprazole. It is created by eHealthMe based on reports of 128,069 people who have side effects when taking Lansoprazole from the FDA, and is updated regularly.

What is Lansoprazole?

Lansoprazole has active ingredients of lansoprazole. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 129,663 Lansoprazole users. Check the latest studies of Lansoprazole.

What is Obliterative bronchiolitis?

Obliterative bronchiolitis (bronchiolar inflammation) is found to be associated with 164 drugs and 489 conditions by eHealthMe. Check the latest studies of Obliterative bronchiolitis.

On Jul, 04, 2026

128,069 people reported to have side effects when taking Lansoprazole.
Among them, 14 people (0.01%) have Obliterative bronchiolitis.

Could Lansoprazole cause Obliterative bronchiolitis?

Among these 14 people:

How long have people been on Lansoprazole when they have Obliterative bronchiolitis? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 100 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Obliterative bronchiolitis when taking Lansoprazole? *

  • female: 57.14 %
  • male: 42.86 %

What is the age of people who have Obliterative bronchiolitis when taking Lansoprazole? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 25.0 %
  • 30-39: 8.33 %
  • 40-49: 8.33 %
  • 50-59: 8.33 %
  • 60+: 50.0 %

What are other drugs people take besides Lansoprazole? *

  1. Methotrexate: 5 people, 35.71%
  2. Folic Acid: 3 people, 21.43%
  3. Hydrocortisone Sodium Phosphate: 3 people, 21.43%
  4. Ursodeoxycholic Acid: 3 people, 21.43%
  5. Ciclosporin: 3 people, 21.43%
  6. Sulfamethoprim: 3 people, 21.43%
  7. Prednisolone: 3 people, 21.43%
  8. Fluconazole: 3 people, 21.43%
  9. Lasix: 2 people, 14.29%
  10. Granisetron Hydrochloride: 2 people, 14.29%

What are other side effects people have besides Obliterative bronchiolitis? *

  1. Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 3 people, 21.43%
  2. Febrile Neutropenia (fever with reduced white blood cells): 3 people, 21.43%
  3. Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 21.43%
  4. Conjunctivitis (pink eye): 3 people, 21.43%
  5. Cytomegalovirus Test Positive: 3 people, 21.43%
  6. High Blood Pressure: 3 people, 21.43%
  7. Acute Graft Versus Host Disease In Skin (acute complication on skin following an allogeneic tissue/blood transplant): 2 people, 14.29%
  8. Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 2 people, 14.29%
  9. Cough: 2 people, 14.29%
  10. Interstitial Lung Disease: 2 people, 14.29%

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 28.57%
  2. Neutrophil Count Decreased (less than normal number of neutrophil a type of blood cell): 3 people, 21.43%
  3. Insomnia (sleeplessness): 3 people, 21.43%
  4. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 3 people, 21.43%
  5. Bone Marrow Conditioning Regimen: 3 people, 21.43%
  6. Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 3 people, 21.43%
  7. High Blood Pressure: 2 people, 14.29%
  8. Secondary Immunodeficiency (lack of immunity due to some disease): 1 person, 7.14%
  9. Cystic Fibrosis (disease of the secretary glands): 1 person, 7.14%
  10. Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Lansoprazole and have Obliterative bronchiolitis?

- Check whether Obliterative bronchiolitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lansoprazole:

Obliterative bronchiolitis treatments and more:

How severe was Obliterative bronchiolitis and when was it recovered:

Expand to all the drugs that have ingredients of lansoprazole:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lansoprazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Obliterative bronchiolitis:

Browse all the conditions that are associated with Obliterative bronchiolitis:

How the study uses the data?

The study uses data from the FDA. It is based on lansoprazole (the active ingredients of Lansoprazole) and Lansoprazole (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.